MGP
MRNA icon

M&G plc’s Moderna MRNA Stock Holding History

M&G plc’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-253,536
Closed -$10.6M – 464
2024
Q4 		$10.6M Buy
+253,536
New +$12.1M 0.07% 195

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

M&G plc's MRNA Position: Q1 2025 in Review

M&G plc sold out of Moderna (MRNA) in Q1 2025, closing a stake of 253,536 shares — an estimated $10.6M sold.

M&G plc first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $10.6M in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • M&G plc reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • M&G plc sold 253,536 Moderna shares in Q1 2025, an estimated $10.6M.
  • M&G plc first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • M&G plc's Moderna position peaked at $10.6M in Q4 2024.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on M&G plc's 13F filing for Q1 2025, filed 13 May 2025.